The Immunology and Biology of Brain Tumors
Immunotherapy has become a viable treatment modality for a variety of cancers (and referred to as Science Magazine's "Breakthrough of the Year" in 2013, as well as ASCO's "Advance of the Year" in both 2016 and 2017). This Special Issue is focused on the relevance of imm...
Saved in:
| Other Authors: | |
|---|---|
| Format: | Book Chapter |
| Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2021
|
| Subjects: | |
| Online Access: | Get Fullteks DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 02512naaaa2200637uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_76275 | ||
| 005 | 20220111 | ||
| 020 | |a books978-3-0365-0103-1 | ||
| 020 | |a 9783036501024 | ||
| 020 | |a 9783036501031 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-0103-1 |c doi | |
| 041 | 0 | |a English | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 100 | 1 | |a Graner, Michael |4 edt | |
| 700 | 1 | |a Graner, Michael |4 oth | |
| 245 | 1 | 0 | |a The Immunology and Biology of Brain Tumors |
| 260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2021 | ||
| 300 | |a 1 electronic resource (88 p.) | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a Immunotherapy has become a viable treatment modality for a variety of cancers (and referred to as Science Magazine's "Breakthrough of the Year" in 2013, as well as ASCO's "Advance of the Year" in both 2016 and 2017). This Special Issue is focused on the relevance of immunobiology in brain tumors, touching on elements of immune suppression, immune stimulation, and the immune microenvironment, with culminations in translational immunotherapy. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine |2 bicssc | |
| 653 | |a vaccine therapy | ||
| 653 | |a oncoantigen | ||
| 653 | |a tumor associate antigen | ||
| 653 | |a tumor angiogenesis | ||
| 653 | |a high-grade glioma | ||
| 653 | |a pituitary neuroendocrine tumors | ||
| 653 | |a VEGF | ||
| 653 | |a Treg | ||
| 653 | |a TAM | ||
| 653 | |a PD-1 | ||
| 653 | |a PD-L1 | ||
| 653 | |a tumor microenvironment (TME) | ||
| 653 | |a glioblastoma multiforme (GBM) | ||
| 653 | |a GBM-associated macrophages (GAMs) | ||
| 653 | |a exosomes | ||
| 653 | |a oncomiR-21 | ||
| 653 | |a STAT3 inhibitor | ||
| 653 | |a glioma | ||
| 653 | |a diffusion tensor imaging | ||
| 653 | |a generalized q-ball imaging | ||
| 653 | |a treatment-related effects | ||
| 653 | |a multiple resections | ||
| 653 | |a adrenal insufficiency | ||
| 653 | |a Addison's disease | ||
| 653 | |a bevacizumab | ||
| 653 | |a cerebral radiation necrosis | ||
| 653 | |a craniopharyngioma | ||
| 653 | |a inflammation | ||
| 653 | |a checkpoint inhibitors | ||
| 653 | |a Interleukin-6 | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/3653 |7 0 |z Get Fullteks |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/76275 |7 0 |z DOAB: description of the publication |